Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IMPAKT Breast Cancer Conference 2013 /
Integrating breast cancer genomics and proteomics

2nd - 4th May 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.05.13
Views: 5174

Dr Gordon Mills - University of Texas MD Anderson Cancer Center, Houston, USA

ecancer reporter Peter Goodwin talks to Dr Mills at the 2013 IMPAKT conference in Brussels about the MD Anderson's current 'Moon Shot' programme looking at the genetics of triple negative breast cancer to take preventative action such as prophlyactic surgery.

They also discuss new assays that look for defects in the function of BRCA1 and BRCA2 genes and the promise of PARP inhibitors in patients with abnormalities in BRCA1 and BRCA 2 genes.


ecancer's filming at IMPAKT has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation